Abiopharma

🔍 Sniecinski Megan (Executive)

Company: Praxis Precision Medicines, Inc. (PRAX)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Acquired 9,625 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,502.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,087 shares of Common Stock at $288.45 per share (Direct)
  Date: 2026-01-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 29,415.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 7,700 shares of Stock Option (Right to Buy) at $294.38 per share (Derivative)
  Date: 2026-01-08 | Code: A | Expires: 2036-01-08 | equity_swap_involved: 0 | shares_owned_after: 7,700.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Ms. Sniecinski was awarded 9,625 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
• F2: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.
• F3: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.